XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
O
O

OpkoHealth

뉴스

Reuters - 42 분 전

U.S. STOCKS Meta Platforms, Cintas, Toast

BUZZ-U.S. STOCKS ON THE MOVE-Meta Platforms, Cintas, Toast Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 bounced back on Thursday, boosted by a recovery in megacaps, as an upbeat forecast from Taiwan Semiconductor Manufacturing lifted chip stocks after a sharp sell-off in the previous session.
A
B
C
F
I
M
M
N
N
O
A
U
U
U
E
M
T
Reuters - 4 시간 전

Opko Health climbs on stock buyback plan

BUZZ-Opko Health climbs on stock buyback plan ** Shares of Opko Health OPK.O up 8.4% premarket to $1.54, highest since beginning of 2024, as biopharma and diagnostics firm plans to buy back stock ** Co announces $100 mln share repurchase program expected to be funded from existing cash and future cash flows ** With ~697 mln shares outstanding, co has ~$990 mln market cap as of Weds ** “We believe OPKO’s shares are significantly undervalued and offer an attractive investment opportunity.
O
Reuters - 5 시간 전

OPKO Health Announces $100 Million Share Repurchase Program

BRIEF-OPKO Health Announces $100 Million Share Repurchase Program July 18 (Reuters) - OPKO Health Inc OPK.O : OPKO HEALTH ANNOUNCES $100 MILLION SHARE REPURCHASE PROGRAM OPKO HEALTH INC - EXPECTS TO FUND REPURCHASE PROGRAM FROM EXISTING CASH AND CASH EQUIVALENTS, AND FUTURE CASH FLOWS Source text for Eikon: ID:nGNXKb9Qb Further company coverage: OP
O
Reuters - 10 시간 전

U.S. Elevance Health, J&J, Primerica

U.S. RESEARCH ROUNDUP-Elevance Health, J&J, Primerica July 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Elevance Health, J&J and Primerica, on Thursday. HIGHLIGHTS * Elevance Health Inc ELV.N : Leerink Partners cuts target price to $620 from $630 * J&J JNJ.N : TD Cowen cuts target price to $185 from $195 * Primerica Inc PRI.N : Jefferies raises target price to $249 from $239 * Travelers Companies Inc TRV.N : HS
A
A
O
P
Q
A
A
C
Reuters - 1 일 전

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates with latest details on Pfizer, Roche and Carmot Therapeutics July 17 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.
A
O
P
R
Reuters - 1 달 전

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R
Reuters - 1 달 전

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R
Reuters - 2 달 전

OPKO Health Inc reports results for the quarter ended in March - Earnings Summary

OPKO Health Inc reports results for the quarter ended in March - Earnings Summary OPKO Health Inc OPK.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of six analysts for the quarter was for a loss of 9 cents per share.
O
Reuters - 2 달 전

OPKO Health Q1 Net Income 81.8 Million

BRIEF-OPKO Health Q1 Net Income USD -81.8 Million May 07 (Reuters) - OPKO Health Q1 revenue from services USD 126.9 million. Q1 operating income USD -71.5 million Q1 pretax profit USD -83.2 million Q1 basic EPS USD -0.12 vs. IBES estimate USD -0.1
O
Reuters - 3 달 전

OPKO Health Inc <OPK.OQ> expected to post a loss of 9 cents a share - Earnings Preview

OPKO Health Inc expected to post a loss of 9 cents a share - Earnings Preview OPKO Health Inc OPK.OQ OPK.O is expected to show a fall in quarterly revenue when it reports results on May 7 for the period ending March 31 2024 The Miami Florida-based company is expected to report a 23.0% decrease in revenue to $182.99 million from $237.6 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on February 27 2024, for the period ended March 31,
O
Reuters - 3 달 전

OPKO Health Inc <OPK.OQ> expected to post a loss of 9 cents a share - Earnings Preview

OPKO Health Inc expected to post a loss of 9 cents a share - Earnings Preview OPKO Health Inc OPK.OQ OPK.O is expected to show a fall in quarterly revenue when it reports results on May 1 (estimated) for the period ending March 31 2024 The Miami Florida-based company is expected to report a 23.0% decrease in revenue to $182.99 million from $237.6 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on February 27 2024, for the period end
O

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.